Withholding Tax on Non-resident Enterprises Clarified, Drug Law Revision for Comment – China Regulatory Brief
Withholding tax on China-sourced income of non-resident enterprises clarified
The State Administration of Taxation (SAT) released an announcement on the administration of withholding tax on China-sourced income derived by non-resident enterprises on October 27, 2017 (“the Announcement”). The Announcement further clarifies matters concerning the withholding of corporate income tax (CIT).
According to the Announcement, the administrative burden of the withholding agents will be reduced. The withholding agent will no longer be required to submit contracts to the tax bureaus for record-filing within 30 days after a contract is signed or amended. Further, the current tax settlement requirement of 15 days prior notice to the last payment is now abolished. The required materials to submit tax returns to the tax bureaus were also simplified.
The Announcement also provides for greater cooperation among different tax bureaus to improve the business environment. For example, when the non-resident enterprise generates income from different tax regions, the withholding agent can choose to pay tax to just one of the relevant tax bureaus.
Moreover, the Announcement clarifies other issues relating to the calculation of taxable income, such as the foreign exchange rule in calculation, the calculation method when the non-resident enterprise accept installments for the payments, as well as how to calculate taxable income in equity transfer and asset transfer.
The Announcement came out with an official interpretation, which contains detailed explanation of the new rules and specific examples. The Announcement will come into force on December 1, 2017, and is expected to be welcomed by both the withholding agents and the non-resident enterprises.
Revised drug administration law, registration measures for comment
The China Food and Drug Administration (CFDA) released revised drafts of the Drug Administration Law and the Administrative Measures for Drug Registration (“the Drafts”) on October 23, 2017 to gather public opinion.
According to the Drafts, China will fully adopt a drug market authorization holder (MAH) system, under which MAHs are responsible for supervising the safety, effectiveness, and quality of their drugs throughout the whole life cycle of the products.
Under the Drafts, the approval regime of clinical trials will be simplified, and overseas trial data will be accepted in drug registration, though an on-site check by CFDA might still be applied.
The Drafts put emphasis on patent and data protection. When applying for market approval, applicants would be required to outline the applications of the patents involved to prevent potential patent infringement. Qualified applicants, such as applicants of innovative drug or drug used for rare diseases, can apply for data protection together with their application for market approval.
Moreover, the examination process for drug registration would be faster, shortening from 150 days to 120 days from the date of acceptance.
As supportive documents of the Guideline on Deepening the Reform of Examination and Approval System and Encouraging Innovation of Drugs and Medical Devices (“the Guideline”) issued on October 8, 2017, the Drafts are generally consistent with the content of the Guideline. However, some rules mentioned in the Drafts, such as patent and data protection, are not specific enough for implementation. More detailed rules are expected to come out soon following the public comment stage.
China Briefing is published by Asia Briefing, a subsidiary of Dezan Shira & Associates. We produce material for foreign investors throughout Asia, including ASEAN, India, Indonesia, Russia, the Silk Road, and Vietnam. For editorial matters please contact us here, and for a complimentary subscription to our products, please click here.
Dezan Shira & Associates is a full service practice in China, providing business intelligence, due diligence, legal, tax, IT, HR, payroll, and advisory services throughout the China and Asian region. For assistance with China business issues or investments into China, please contact us at email@example.com or visit us at www.dezshira.com
Dezan Shira & Associates is a pan-Asia, multi-disciplinary professional services firm, providing legal, tax and operational advisory to international corporate investors. Operational throughout China, ASEAN and India, our mission is to guide foreign companies through Asia’s complex regulatory environment and assist them with all aspects of establishing, maintaining and growing their business operations in the region. This brochure provides an overview of the services and expertise Dezan Shira & Associates can provide.
This Dezan Shira & Associates 2017 China guide provides a comprehensive background and details of all aspects of setting up and operating an American business in China, including due diligence and compliance issues, IP protection, corporate establishment options, calculating tax liabilities, as well as discussing on-going operational issues such as managing bookkeeping, accounts, banking, HR, Payroll, annual license renewals, audit, FCPA compliance and consolidation with US standards and Head Office reporting.
China’s foreign investment landscape has experienced pivotal changes this year. In this issue of China Briefing magazine, we examine how foreign investors can capitalize on China’s latest FDI reforms. First, we outline new industry liberalizations in both China’s FTZs and the country at large. We then consider when an FTZ makes sense as an investment location, and what businesses should consider when entering one. Finally, we give an overview of China’s latest pro-business reforms that streamline a wide range of administrative and regulatory measures.